Allergies News and Research

Latest Allergies News and Research

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Phadia, the world leader in allergy blood testing diagnostics, today announced that the United States Food and Drug Administration (FDA) has cleared the ImmunoCAP® Rapid Reader II, a part of the ImmunoCAP Rapid System, used to aid in the diagnosis of allergy in the physician’s office.

27 Jan 2010

NTNU: 40% of two-year-olds report allergy-related disorders

Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood? In a population-based study designed to help answer this question, researchers at the Norwegian University of Science and Technology (NTNU) found that 40 per cent - or two of five -- of nearly 5,000 two-year-olds had at least one reported allergy-related disorder. The most common symptom was wheezing, which was reported in 26 per cent of all children in the study, says Ingeborg Smidesang, a PhD candidate in the university's Faculty of Medicine, and the primary author of the study.

25 Jan 2010

OrbusNeich's clinical data demonstrates the benefits of Genous Bio-engineered R stent

OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

24 Jan 2010

Researchers to study the impact of asthma on sleep and academic performance of young children

Bradley Hasbro Children's Research Center and Hasbro Children's Hospital researchers have received more than $2.5 million in direct costs from The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to study the impact of asthma on the sleep quality and academic performance of young children.

22 Jan 2010

First DataBank signs licensing agreement with SIS

First DataBank, a leading provider of drug databases that help drive patient safety, and Surgical Information Systems (SIS), a provider of feature-rich perioperative software solutions, announced today they have signed an agreement whereby First DataBank will license its suite of comprehensive drug information and associated developer software to Surgical Information Systems to enable the integration of new functionality for drug screening, dosing and documentation within the SIS suite of interoperable surgery solutions.

21 Jan 2010

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

Duke University has received a $3.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid and accurate genomic-based diagnostic test that can determine if a person has been exposed to radiation from a dirty bomb or nuclear attack. In the event that all option years are exercised by the government, Duke University could receive up to $43.6 million from the contract.

21 Jan 2010

Study identifies new mechanism that causes allergic response in people

WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.

21 Jan 2010

Acyclovir does not reduce risk of HIV transmission for people infected with both HIV and HSV-2

A five-year international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment taken twice daily to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.

21 Jan 2010

QuantRx Biomedical's developments in genetics-based technology

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today provided an update from Chairman and Chief Executive Officer Walter Witoshkin on its involvement in genetics-based personalized medicine and disease prevention.

20 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

Journal Homeopathy highlights a remarkable range of findings on homeopathic treatments

The journal Homeopathy (http://www.elsevier.com/locate/homp) has published a two part special issue focusing on biological models of homeopathy. The special issue highlights experiments on homeopathic treatments in biological models, ranging from whole animals and plants to cell cultures and enzymes, showing a remarkable range of findings.

19 Jan 2010

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

18 Jan 2010

Whitley urges public to get vaccinated against H1N1 influenza virus

With several months left in the influenza season and growing supplies of vaccine, now is an opportune time to get vaccinated against the 2009 H1N1 influenza virus, says Richard Whitley, M.D., director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases and current president of the Infectious Diseases Society of America (IDSA).

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Officials from the National Institutes of Health and the city of Washington, D.C. today announced the new D.C. Partnership for HIV/AIDS Progress, a collaborative research initiative between NIH and the D.C. Department of Health designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic.

13 Jan 2010

Phase I clinical trial of XRX-001 for yellow fever initiated

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Allscripts introduces Allscripts Stimulus Program for physicians

Allscripts today introduced the Allscripts Stimulus Program, making it safe and easy for physicians to purchase and rapidly deploy Electronic Health Records that will qualify for significant federal incentives.

11 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

Allergies News and Research

Latest Allergies News and Research

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

NTNU: 40% of two-year-olds report allergy-related disorders

OrbusNeich's clinical data demonstrates the benefits of Genous Bio-engineered R stent

Researchers to study the impact of asthma on sleep and academic performance of young children

First DataBank signs licensing agreement with SIS

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

Study identifies new mechanism that causes allergic response in people

Acyclovir does not reduce risk of HIV transmission for people infected with both HIV and HSV-2

QuantRx Biomedical's developments in genetics-based technology

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Journal Homeopathy highlights a remarkable range of findings on homeopathic treatments

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

Whitley urges public to get vaccinated against H1N1 influenza virus

University of Leicester study provides new insights into preventer and reliever treatments for asthma

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Phase I clinical trial of XRX-001 for yellow fever initiated

VentiRx Pharmaceuticals completes $25 million Series A Extension

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allscripts introduces Allscripts Stimulus Program for physicians

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Allergies News and Research

Latest Allergies News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in